Daiichi Sankyo forges $12M pact for GPCR pain program with Heptares; Incyte shares jump on latest takeover chatter
→ Heptares struck a $12 million deal to partner with Daiichi Sankyo on a new GPCR pain drug. The UK biotech gets $4 million upfront and $8 million in research support along with an unspecified set of milestones for the deal, in which the Sosei subsidiary will search for new drugs that can be developed for pain. Said CEO Malcolm Weir: “We are confident that the unique structural insights of the receptor that our technologies can deliver combined with expertise on its role in pain from the Neurosciences team at Daiichi Sankyo will yield new, differentiated molecules that can be advanced into development.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
